3374-05-8 Usage
Description
Nalidixic acid sodium salt is a synthetic chemotherapeutic agent belonging to the quinolone class of antibiotics. It exhibits broad-spectrum antimicrobial activity and is particularly effective against gram-negative bacteria. Nalidixic acid sodium salt works by inhibiting bacterial DNA synthesis, thereby disrupting the bacterial cell's replication and growth.
Uses
Used in Pharmaceutical Industry:
Nalidixic acid sodium salt is used as an antibacterial agent for the treatment of various bacterial infections, particularly those caused by gram-negative bacteria. It acts as an inhibitor of bacterial DNA polymerase and avian myeloblastoma virus reverse transcriptase, effectively blocking nucleic acid and protein synthesis in bacteria such as Escherichia coli and Salmonella.
Used in Research Applications:
In addition to its clinical use, nalidixic acid sodium salt is also utilized in research settings as a tool to study the mechanisms of bacterial DNA replication and the development of antibiotic resistance. Its ability to inhibit DNA synthesis in Saccharomyces cerevisiae makes it a valuable compound for investigating the fundamental processes of DNA replication and the potential for developing new antimicrobial agents.
Used in Veterinary Medicine:
Nalidixic acid sodium salt is also employed in veterinary medicine for the treatment of bacterial infections in animals. Its broad-spectrum activity and effectiveness against gram-negative bacteria make it a useful option for managing infections in various animal species.
Biochem/physiol Actions
Nalidixic acid sodium salt is an inhibitor of bacterial DNA polymerase (DNA gyrase) and avian myeloblastoma virus reverse transcriptase. Inhibits nucleic acid and protein synthesis in Saccharomyces cerevisiae.
Check Digit Verification of cas no
The CAS Registry Mumber 3374-05-8 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,3,7 and 4 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 3374-05:
(6*3)+(5*3)+(4*7)+(3*4)+(2*0)+(1*5)=78
78 % 10 = 8
So 3374-05-8 is a valid CAS Registry Number.
InChI:InChI=1/C12H12N2O3.Na/c1-3-14-6-9(12(16)17)10(15)8-5-4-7(2)13-11(8)14;/h4-6H,3H2,1-2H3,(H,16,17);/q;+1/p-1
3374-05-8Relevant articles and documents
Structural and morphological aspects of (fluoro)quinolone delivery by layered double hydroxide nanoparticles
Salguero, Yadira,García, Mónica Cristina,Mosconi, Giuliana,Rojas, Ricardo
, p. 19144 - 19152 (2018)
Layered double hydroxides (LDHs) have been proposed as delivery systems (DSs) of (fluoro)quinolones (QLNs) to overcome their low bioavailability and to prevent the emergence of resistant bacteria. Both LDH-DS synthesis as nanoparticles (NPs) and QLN interactions with the metal ions that constitute the layers are essential to improve their physicochemical, biopharmaceutical and antimicrobial properties. Here, LDH-DSs containing the basic form of nalidixic acid (Nal), used as a probe, were obtained by coprecipitation at variable and constant pH (LDH-Nal-pHvar and LDH-Nal-pHcte, respectively). For both syntheses, LDH NPs containing Nal anions (LDH-Nal-NPs), with sizes between 30 and 40 nm, were obtained. A coordination compound (Mg(Nal)2·4H2O, Mg(Nal)2) was also concurrent for LDH-Nal-pHcte, which modulated the drug release profile and antimicrobial properties of the LDH-Nal-NPs. Thus, Nal release from LDH-Nal-pHvar was produced mainly by anion exchange. The best fits, obtained for the Higuchi model, showed rate constants dependent on the exchanging anions (kH = 0.88 and 1.53 for NaCl 0.9% and buffer phosphate 0.05 M, pH = 7.4, respectively). The nanometric size of LDH-Nal-pHvar as well as its faster release rate allowed a minimum inhibitory concentration decrease (MIC = 32 μg mL?1) compared to the pure drug (MIC = 128 μg mL?1). Instead, the presence of Mg(Nal)2 in LDH-Nal-pHcte led to a more sustained and media independent Nal release, but a lower MIC (64 μg mL?1) than LDH-Nal-pHvar.
